Friday, 16 Nov 2018

You are here

Two Lupus Studies

In this session we were given new data on ustekinumab for SLE (abstract 6L). Ustekinumab is an IL12/23 agent already approved for use in psoriasis, psoriatic arthritis and Cohn’s disease. This abstract presented results from a Phase II trial in active SLE. The trial enrolled 102 active SLE patients who were randomised to ustekimumab or placebo (3:2 ratio) and followed for 24 weeks with the SRI-4 being used as the primary end-point.  At week 24, the primary end-point was achieved in 60% of ustekinumab and 31% of placebo patients (p=0.0046). The risk of a flare was also lower in the ustekinumab treated group (p=0.0078). Skin and joint disease activity improved more in the ustekinumab group in those with activity in these organs at baseline. There were no significant imbalances in serious adverse events between the groups. A Phase III trial is now in development. 

Of interest, an abstract (2609) on Tuesday reported a data driven approach to literature mining to aid in identifying new potential targets for SLE therapy and using an objective scoring system. This approach had previously assessed ustekinumab as a potential target of interest in SLE. The results of this Phase II trial are also therefore nice proof of concept data to support this approach. Abstract 2609 reporting the literature mining exercise has also identified an additional 25 potential drugs for repurposing in SLE.

Hopefully there will be more to come both from this agent and the others from this pipeline to help address the significant unmet need in SLE.  

Add new comment

More Like This

Pilot Data on Rituximab in Henoch-Schonlein Purpura

Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.

Scleroderma Expert Treatment Preferences

Frustration may be the word that best characterizes many scleroderma management plans - owing to a lack of trials, lack of agreement and lack of clear guidance on management.

A panel of concerned experts  on systemic sclerosis (SSc) set out to develop consensus on SSc treatment algorithms.

IgG4-Related Disease: First Draft Criteria Presented at ACR 2018

As Dr. John Stone, MD, MPH recounted in his presentation regarding the new ACR/EULAR Classification Criteria for IgG4-Related Disease (IgG4-RD), only 15 years prior, IgG4-related disease was an unknown entity in the medical community.

Update on Myositis

The ACR/ARHP 2018 national meeting in Chicago presented us with opportunities to learn more about inflammatory myositis. A particularly interesting lecture was HOT topics in myositis. There were a few abstracts on MDA-5 related disease and a few on new or repurposed medications for dermatomyositis which will be covered here.

Checkpoint Inhibitor-related Myositis – Something Different

As expected, this year’s ACR meeting saw an upswing in the number of abstracts on immune related adverse events from checkpoint inhibitor therapy compared to last year. With the increase in approved indications for checkpoint inhibitors (CPIs), rheumatologists everywhere are going to be getting referrals for rheumatic irAEs.